Historical moment for Alzheimer’s treatment

Re:Cognition Health proud to deliver lecanemab clinical trial

Historical moment for Alzheimer’s treatment

Re:Cognition Health proud to deliver lecanemab clinical trial

Re:Cognition Health’s Brain and Mind Experts are excited and proud to be delivering
“Clarity“ the global clinical trial for Lecanemab, as the result of the trial is being hailed by
Alzheimer’s international experts as an “historic moment”. Re:Cognition Health’s team are
optimistic the results could lead to the progression of an effective potential treatment for
Alzheimer’s disease in the UK.

1,795 volunteers in the early stages of Alzheimer’s participated in this trial, receiving
fortnightly infusions of lecanemab, a new medication developed by pharmaceutical
companies Eisai and Biogen. Results demonstrated a 27% reduction in the rate of
progressive cognitive decline for those on lecanemab compared to those on a placebo, in an
18-month trial.

Dr Emer MacSweeney, the CEO and Medical Director at Re:Cognition Health and the
Principal Investigator for the trial comments, “We are always encouraged by the results of
clinical trials, as it enables us to understand more about Alzheimer’s disease pathology and
potential treatments. The results of lecanemab are very exciting, not only as a treatment for
those with early stages of Alzheimer’s, but also in forging a pathway for the development of
multiple new treatments. There are many new drugs currently in clinical trials for various
stages of Alzheimer’s disease and it’s certainly a very exciting time with cause for optimism.”

Re:Cognition Health is one of the world’s leading clinics for delivering international clinical
trials for Alzheimer’s and other causes of dementia at its multiple centres in London,
Birmingham, Bristol, Guildford, Plymouth, Winchester UK and Washington DC and soon to
open Houston and Chicago USA. These clinical trials are essential for advancing our
understanding of medicine and improving the healthcare and quality of life for everyone
affected by cognitive impairment.

As with any neurodegenerative condition, early access is imperative in helping to access
treatments, particularly for enrolment in clinical trials.

Some of the early warning signs of dementia can include:

  • Short-term memory loss such as forgetting names and important dates and
    repeatedly asking the same questions
  • Changes in behaviour – unexpected & uncharacteristic anxiety and changes in mood,
    perhaps becoming passive and disinterested, or easily angered.
  • Confusion which could include losing track of time or problems with processing
  • Forgetting words and experiencing problems with speech and language
  • Loss of sense of direction, getting lost in a familiar environment and disorientated
  • Difficulty in performing every day (seemingly normal) tasks such as making a cup of
    tea or unpacking the grocery shopping
  • Problems with calculation – managing money or completing simple sums and puzzles
    may become an issue
  • Misplacing items such as putting keys in freezer or milk in the dishwasher and not
    being able to retrace steps to find them
  • Difficulty making decisions which may also include making the wrong decision such
    as personal grooming
  • Issues with visual images and spatial awareness which may include difficulty reading
    words, judging distances or recognising colour contrast

Anyone over 50 experiencing 2 or more of these symptoms, which have been gradually
progressing over the past 12 months, should consult with their GP or contact Re:Cognition
Health to find out about clinical trials for other new medications similar to lecanemab.

For further information and for interviews with Dr MacSweeney, please contact:

Alina Wallace: 07946 189672 / alina@alinawallace.com

About Re:Cognition Health: Re:Cognition Health is a pioneering brain and mind clinic specialising in
the diagnosis, treatment and care of people showing symptoms of cognitive impairment or mental
health concerns. Clinical services include traumatic brain injury, neurology, children’s neurological
conditions, Alzheimer’s and dementia, mental health, long Covid and cannabis. The Re:Cognition
Health Clinics in Birmingham, Bristol, London, Surrey, Plymouth, Winchester and Washington DC are
also major centres for international trials of disease-modifying and new symptomatic drugs for
Alzheimer’s disease and other neurological conditions. The multi-disciplinary team work
collaboratively to provide a full-service, patient-centred approach using the latest progressive medical
research and evidence-based treatments.